0001654954-20-000270.txt : 20200110
0001654954-20-000270.hdr.sgml : 20200110
20200110141335
ACCESSION NUMBER: 0001654954-20-000270
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200108
FILED AS OF DATE: 20200110
DATE AS OF CHANGE: 20200110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: van der Velden Peter
CENTRAL INDEX KEY: 0001778046
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37619
FILM NUMBER: 20520568
MAIL ADDRESS:
STREET 1: C/O EDESA BIOTECH INC.
STREET 2: 100 SPY COURT
CITY: MARKHAM
STATE: A6
ZIP: L3R 5H6
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lumira Capital Investment Management Inc.
CENTRAL INDEX KEY: 0001702636
STATE OF INCORPORATION: Z4
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37619
FILM NUMBER: 20520569
BUSINESS ADDRESS:
STREET 1: 141 ADELAIDE STREET WEST
STREET 2: SUITE 770
CITY: TORONTO
STATE: A6
ZIP: M5H 3L5
BUSINESS PHONE: 416-213-4223
MAIL ADDRESS:
STREET 1: 141 ADELAIDE STREET WEST
STREET 2: SUITE 770
CITY: TORONTO
STATE: A6
ZIP: M5H 3L5
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Edesa Biotech, Inc.
CENTRAL INDEX KEY: 0001540159
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 100 SPY COURT
CITY: MARKHAM
STATE: A6
ZIP: L3R 5H6
BUSINESS PHONE: (905) 475-1234
MAIL ADDRESS:
STREET 1: 100 SPY COURT
CITY: MARKHAM
STATE: A6
ZIP: L3R 5H6
FORMER COMPANY:
FORMER CONFORMED NAME: Stellar Biotechnologies, Inc.
DATE OF NAME CHANGE: 20120120
4
1
section16.xml
PRIMARY DOCUMENT
X0306
4
2020-01-08
0001540159
Edesa Biotech, Inc.
EDSA
0001778046
van der Velden Peter
C/O EDESA BIOTECH INC.
100 SPY COURT
MARKHAM
A6
L3R 5H6
ONTARIO, CANADA
true
true
0001702636
Lumira Capital Investment Management Inc.
141 ADELAIDE STREET WEST
SUITE 770
TORONTO
A6
M5H 3L5
ONTARIO, CANADA
true
true
Common Shares
2020-01-08
4
P
false
128722
3.20
A
1833066
I
Held by Lumira Capital II, L.P.
Common Shares
2020-01-08
4
P
false
11903
3.20
A
169502
I
Held by Lumira Capital II (International), L.P.
Common Share Warrants (Right to Buy)
4.80
2020-01-08
4
P
false
96542
A
2020-07-08
2023-07-08
Common Shares
96542
96542
I
Held by Lumira Capital II, L.P.
Common Share Warrants (Right to Buy)
4.80
2020-01-08
4
P
false
8928
A
2020-07-08
2023-07-08
Common Shares
8928
8928
I
Held by Lumira Capital II (International), L.P.
Common Share Warrants (Right to Buy)
4.00
2020-01-08
4
P
false
64362
A
2020-07-08
2020-11-08
Common Shares
64362
64362
I
Held by Lumira Capital II, L.P.
Common Share Warrants (Right to Buy)
4.00
2020-01-08
4
P
false
5952
A
2020-07-08
2020-11-08
Common Shares
5952
5952
I
Held by Lumira Capital II (International), L.P.
The reported securities are included within 128,722 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share.
The reported securities are included within 11,903 Common Shares purchased by the reporting person for $3.20 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share.
This Form 4 is jointly filed by (i) Lumira Capital II, L.P. ("LCII LP"), (ii) Lumira Capital II (International), L.P. ("LCII INT LP"), (iii) Lumira Capital GP, L.P., (iv) Lumira GP Inc., (v) Lumira GP Holdings Co., and (vi) Lumira Capital Investment Management Inc. Lumira Capital GP, L.P., the general partners of which are Lumira GP Inc. and Lumira GP Holdings Co., is the general partner of LCII LP and LCII INT LP, and each of LCII LP and LCII INT LP is managed by Lumira Capital Investment Management Inc. Mr. van der Velden is an executive officer of Lumira GP Inc., Lumira GP Holdings Co., and Lumira Capital Investment Management Inc. Each of Lumira Capital GP, L.P., Lumira GP Inc., Lumira GP Holdings Co., Lumira Capital Investment Management Inc. and Mr. van der Velden may be deemed to beneficially own the shares held by LCII LP and LCII INT LP, but each disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any.
Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023.
Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020.
/s/ Peter van der Velden
2020-01-10
/s/ Vasco Larcina
2020-01-10